TriangleNCT02576990 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to approximately 27 months (Database Cutoff Date: 28MAY2019)
What was measured
OS was defined as the time from the first dose to death due to any cause. OS is presented from product limit (Kaplan-Meier) method for censored data (censored at the last assessment).
Analysis population: The analysis population included all participants who received at least one dose of study medication (pembrolizumab).
Groups in this outcome
Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
Pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).
Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)
Pembrolizumab 200 mg Q3W, IV on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).
| Group | Source count |
|---|---|
| Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) | 53 |
| Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS) | 23 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) | 22.3 | Not reported | 7.3 | NA | NA = OS upper limit was not reached (insufficient number of deaths by time of last disease assessment). |
| Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS) | 3.8 | Not reported | 1.8 | 18.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- comment
- NA = OS upper limit was not reached (insufficient number of deaths by time of last disease assessment).
- group Id
- OG000
- lower Limit
- 7.3
- upper Limit
- NA
- value
- 22.3
- group Id
- OG001
- lower Limit
- 1.8
- upper Limit
- 18.1
- value
- 3.8
- denoms
- counts
- group Id
- OG000
- value
- 53
- group Id
- OG001
- value
- 23
- units
- Participants
- description
- OS was defined as the time from the first dose to death due to any cause. OS is presented from product limit (Kaplan-Meier) method for censored data (censored at the last assessment).
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).
- id
- OG000
- title
- Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
- description
- Pembrolizumab 200 mg Q3W, IV on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).
- id
- OG001
- title
- Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)
- param Type
- MEDIAN
- population Description
- The analysis population included all participants who received at least one dose of study medication (pembrolizumab).
- reporting Status
- POSTED
- time Frame
- Up to approximately 27 months (Database Cutoff Date: 28MAY2019)
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice